Published:24/11/2020
Contract Pharma recently published an in-depth article by Sandy Munro, VP Pharmaceutical Development, titled “Inhaled Drug Delivery Technology Trends”. Sandy shares his considerations about platform options, optimal device selection and phase-appropriate choices.
“A methodical approach should be taken to analyze the advantages and potential drawbacks of all the options, narrowing down the choices based on the molecule’s properties, the technical requirements, any demands for speed and cost, and with a clear focus on the intended patient population.”
For more, click here.